Summary
Enzyme replacement therapy (ERT) with laronidase, recombinant α-l-iduronidase, for mucopolysaccharidosis type I (MPS I) has been clinically available since April 2003. Pre-approval studies were performed on patients with the more attenuated forms of MPS I, Hurler–Scheie and Scheie syndromes. The clinical efficacy of laronidase on the severe form of MPS I, Hurler syndrome, is not well known. We present a patient with Hurler syndrome who has been treated with laronidase for 3 years. Clinically, the patient demonstrated improvement in urinary glycosaminoglycan (GAG) levels and hepatomegaly, but continued to experience decline in respiratory status, musculoskeletal and spinal involvement, and developmental skills. Overall, the benefit of ERT with laronidase in advanced Hurler syndrome appeared to be minimal in this patient.
Author information
Authors and Affiliations
Corresponding author
Additional information
Communicating editor: Douglas Brooks
Electronic Supplementary Material
Rights and permissions
About this article
Cite this article
Thomas, J.A., Jacobs, S., Kierstein, J. et al. Outcome after three years of laronidase enzyme replacement therapy in a patient with Hurler syndrome. J Inherit Metab Dis 29, 762 (2006). https://doi.org/10.1007/s10545-006-0457-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10545-006-0457-y